All T2DM patients received combination therapy comprising a biguanide derivative (metformin) and sodium-glucose co-transporter type 2 inhibitors (SGLT-2is) or glucagon-like peptide-1 receptor agonists (GLP-1RAs). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.